Amgen Inc. $AMGN Stock: Stokes Capital Advisors LLC Increases Position

Stokes Capital Advisors LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 187.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,811 shares of the medical research company’s stock after purchasing an additional 5,750 shares during the quarter. Stokes Capital Advisors LLC’s holdings in Amgen were worth $3,714,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rational Advisors Inc. boosted its position in shares of Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after acquiring an additional 24 shares during the last quarter. Beacon Financial Advisory LLC grew its holdings in shares of Amgen by 2.0% in the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after purchasing an additional 25 shares during the period. Legacy Financial Advisors Inc. increased its position in Amgen by 0.8% during the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after purchasing an additional 26 shares during the last quarter. Roman Butler Fullerton & Co. increased its position in Amgen by 1.4% during the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after purchasing an additional 27 shares during the last quarter. Finally, Round Rock Advisors LLC raised its stake in Amgen by 2.9% during the second quarter. Round Rock Advisors LLC now owns 1,003 shares of the medical research company’s stock worth $363,000 after purchasing an additional 28 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last ninety days. Insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS upgraded Amgen to Buy and raised its price target to $470 from $430, implying further upside from the reported $414.87 share price. The upgrade is the clearest near-term catalyst behind the stock’s strength. Benzinga analyst upgrade report
• Positive Sentiment: Amgen announced a head-to-head Phase 3 trial for its monthly diabetes drug candidate against semaglutide. Success could strengthen the company’s position in the highly competitive GLP-1 market and provide a significant future growth opportunity, although clinical and commercial risks remain. Amgen monthly diabetes trial article
• Positive Sentiment: Cantor Fitzgerald raised its Amgen price target to $440 from $400, signaling improved expectations despite maintaining a Hold rating. Cantor Fitzgerald price target report

Wall Street Analyst Weigh In

AMGN has been the topic of several recent analyst reports. Piper Sandler boosted their target price on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Sanford C. Bernstein lifted their price target on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. UBS Group upped their price objective on Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday. Royal Bank Of Canada increased their price objective on Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Argus lifted their target price on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $389.71.

Amgen Stock Performance

Shares of AMGN stock opened at $414.87 on Friday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm has a market cap of $224.29 billion, a P/E ratio of 25.78, a P/E/G ratio of 2.94 and a beta of 0.41. The firm’s 50 day moving average price is $412.94 and its 200-day moving average price is $372.18. Amgen Inc. has a one year low of $288.00 and a one year high of $447.03.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s payout ratio is presently 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.